Treatment options for Alzheimer disease (AD) are limited and have focused mainly on symptomatic therapy and improving quality of life. Research on the applicability and generalizability of the anti–β-amyloid mAb eligibility criteria on adults with biomarkers available in the general population has been lacking. This study’s primary aim was to apply the clinical trial eligibility criteria for lecanemab treatment to participants with early AD of the population-based Mayo Clinic Study of Aging (MCSA) and assess the generalizability of anti-amyloid treatment. The secondary aim of this study was to apply the clinical trial eligibility criteria for aducanumab treatment in MCSA participants.
Link: Neurology (11/2023)
